PTC THERAPEUTICS, INC. — Form 8-K
Filed July 30, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
PTC reported Q2 2026 total revenue of $361 million ($239M product revenue), with Sephience generating $151M. The company raised full-year 2026 total revenue guidance to $1.18–$1.28 billion (product revenue $850–$950M, up from $750–$850M prior guidance). Key events: $50M milestone payment from Novartis triggered by INVEST-HD Phase 3 initiation; $550M convertible notes issued at 0% coupon; cash position $2.229 billion; 83.3M shares outstanding.
Why this rating
Strong Q2 performance and raised guidance meaningful for $3.4B market cap company; Sephience scaling rapidly; $50M Novartis milestone material. Execution risk remains.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.